Compare Abbott Laboratories (ABT) vs MasterCard Inc (MA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs MasterCard Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while MasterCard Inc trades at $532 (market cap $469.73B). The key difference: MasterCard Inc is far larger — about 2.8× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MA | |
|---|---|---|
Market Cap | $166.94B | $469.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $598.96 |
52-Week Low | $82.57 | $471.55 |
Enterprise Value | $193.69B | $480.47B |
Dividend Yield | 2.63% | 0.65% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Mastercard (MA) trades at $519.94, down 2.47% on the day, with a bullish technical outlook from moving averages and a consensus analyst price target of $637.67. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding expectations. Revenue grew to $32.79 billion in 2025, and net income margin remains robust at 45.88%. Recent news highlights institutional buying and strategic initiatives in AI and financial inclusion.
The stock presents a compelling growth opportunity given its consistent earnings outperformance, high profitability, and positive analyst sentiment. Key risks include competitive pressures from emerging payment technologies like stablecoins and potential regulatory scrutiny. With no sell ratings and significant institutional accumulation, the fundamental and sentiment backdrop supports a bullish outlook, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
